Novo Nordisk A/S reported on September 16, 2024, about its ongoing share repurchase program initiated on August 7, 2024, with a target of up to DKK 20 billion over 12 months, having already repurchased 12,235,249 B shares for about DKK 10.78 billion at an average price of DKK 881.30 per B share.